Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Other solid neoplasm 8Head & Neck 2Genitourinary 2Dermatologic 2Gastrointestinal 1Endocrine 1Breast 1

Conditions

Melanoma 38Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Carcinoma, Merkel Cell 8Uterine Cervical Neoplasms 7Stomach Neoplasms 7Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Small Cell Lung Carcinoma 5Neoplasms 5Kidney Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Esophageal Neoplasms 3Breast Neoplasms 3Urogenital Neoplasms 2Skin Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Neoplasms by Histologic Type 2Microsatellite Instability 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Squamous Cell 2

Interventions

pembrolizumab 2atezolizumab 2Nivolumab 2entinostat 1durvalumab 1cemiplimab 1bemcentinib 1avelumab 1Polymerase Chain Reaction 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1In Situ Hybridization, Fluorescence 1Immunoglobulin G 1Immunoenzyme Techniques 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Etoposide 1Docetaxel 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × atezolizumab × Dermatologic × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡